Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced that the US Patent and Trademark Office (USPTO) has granted U.S. patent number US11191784, titled “The Methods and Composition for Gene Delivery Using an Engineered Viral Particle.”
Interius is rethinking how genetic therapies can be used and is developing a novel platform to enable an efficacious, potentially safer, and more accessible set of therapies to address diseases driven by single gene mutations as well as complex diseases, such as cancers. Interius was recently named “Deal of the Year” by The Penn Center for Innovation at its sixth annual Celebration of Innovation. The award validates the importance of the scientific mission of the company to develop transformational genetic medicines.